Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICS Study in Resectable Gastric Cancer
NCT00407186Phase 3Active, not recruiting
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Jan 2007
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, capecitabine and epirubicin in gastric cancer (GC) (2 arms), sponsored by Dutch Colorectal Cancer Group. Primary endpoint: Overall Survival. Started Jan 2007; status: active, not recruiting.
02
Drugs
cisplatincapecitabineepirubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00407186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00407186.